Dow Up0.12% Nasdaq Up1.35%

Prothena Corporation plc (PRTA)

20.14 0.18(0.90%) Oct 20, 4:00PM EDT
ProfileGet Profile for:
Prothena Corporation plc
25 - 28 North Wall Quay
Dublin, 1
Ireland - Map
Phone: 353 1 902 3519
Fax: 353 1 902 3510

Index Membership:N/A
Full Time Employees:39

Business Summary 

Prothena Corporation plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion. Its product pipeline includes NEOD001, a product candidate in Phase 1 clinical trial to target AL and AA forms of amyloidosis; PRX002 for the treatment of Parkinson’s disease and related synucleinopathies; and PRX003 for the treatment of inflammatory disease and metastatic cancers. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Prothena Corporation plc

Corporate Governance 
Prothena Corporation plc’s ISS Governance QuickScore as of Oct 1, 2014 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 3; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Dale B. Schenk Ph.D., 57
Chief Exec. Officer and Director
Mr. Tran B. Nguyen M.B.A., 40
Chief Financial Officer
Mr. Gene G. Kinney Ph.D., 45
Chief Scientific Officer and Head of R&D
Ms. Karin L. Walker , 51
Chief Accounting Officer and Controller
Mr. Arthur W. Homan , 55
Chief Legal Officer
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders